Results 111 to 120 of about 12,992 (201)

Continued Eculizumab Therapy for Persistent Atypical Hemolytic Uremic Syndrome

open access: yes, 2013
Atypical hemolytic uremic syndrome (atypical HUS) is characterized by endothelial injury and microvascular thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia, and ischemic injury to organs, especially the kidney.
Vachharajani, Tushar   +5 more
core   +1 more source

Disseminated cryptococcosis associated with administration of eculizumab.

open access: yes, 2018
PURPOSE: A case report of fatal disseminated cryptococcosis in a patient treated with eculizumab is presented along with a review of literature suggesting a possible etiologic mechanism.
Iaderosa, Roberto   +6 more
core   +1 more source

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

open access: yesAdvances in Hematology, 2014
Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy
Han-Mou Tsai, Elizabeth Kuo
doaj   +1 more source

Clinical predictors of mortality in immune thrombotic thrombocytopenic purpura: A National Inpatient Sample analysis

open access: yes
British Journal of Haematology, Volume 209, Issue 3, Page 1415-1418, September 2026.
Anand Shah   +4 more
wiley   +1 more source

Hemolysis in eculizumab-treated PNH patients

open access: yes, 2017
35 p.-3 fig.-4 tab. Subías, Marta et al.Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is effectively treated with eculizumab. However, treatment responses are
Anter, Jaouad   +5 more
core   +1 more source

Eculizumab Therapy [PDF]

open access: yesBiology of Blood and Marrow Transplantation, 2014
openaire   +2 more sources

The use of eculizumab in renal transplantation

open access: yes, 2013
The complement system plays a vital role in mediating disease processes within renal allografts. Eculizumab is a humanized monoclonal antibody that targets complement protein C5, inhibiting cleavage into C5a and C5b, and therefore preventing formation of
Dorling, Anthony; id_orcid   +5 more
core   +1 more source

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

open access: yesJournal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +1 more source

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

open access: yes, 2011
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder with increased mortality and morbidity resulting from intravascular hemolysis.
Richard J. Kelly   +9 more
core   +1 more source

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report

open access: yesClinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen Halka Department of Hematology/Oncology, Scott & White Healthcare and The Texas A&M Health Science Center, College of Medicine, Temple, TX, USA Objective: To describe how maintenance eculizumab ...
Halka K, Cable C, Ohanian M
doaj  

Home - About - Disclaimer - Privacy